In this study we aimed to evaluate the impact of doxazosin treatment on erectile functions in patients with lower urinary tract symptoms (LUTS) and having erectile dysfunction (ED) at baseline. Fifty-three patients with LUTS (IPSS score > 7) whose maximum flow rate (Qmax) < 15 mL s^-1 and PSA < 4 ng dL^-1 were enrolled in the study. Patients received doxazosin 4 mg once daily for 6 weeks. Subjective efficacy was assessed by IPSS, IPSS-Quality of Life (IPSS-QoL) for LUTS and efficacy was assessed by International Index of Erectile Function (IIEF) for erectile functions at baseline and sixth weeks. The objective efficacy was assessed by Qmax. The patients were classified according to their self reported erectile status: group I had ED and group II did not have ED. At the endpoint, doxazosin significantly improved the total IPSS score (–7.7 ± 6.1, P = 0.006), IPSS-QoL score (–1.5 ± 1.5, P = 0.024) and Qmax (3.2 ± 4.6 mL s^-1, P = 0.002) over baseline. Mean decrease in IPSS and IPSS-QoL scores after the treatment period were 6.9 ± 6.4 (P < 0.001) and 0.95 ± 1.80 (P < 0.05) in group I, whereas 8.2 ± 5.8 (P < 0.001) and 1.9 ± 1.1 in group II (P < 0.001), respectively. Mean changes of Qmax values were 2.3 3.3 mL s^-1 in group I (P < 0.05) and 3.7± 5.3 mL s^-1 in group II (P < 0.001). The improvement of IIEF-EF scores after the treatment period was only significant for group I. The efficacy of -blocker therapy for LUTS was better by means of symptomatic relief for patients who did not have ED when compared with patients who had ED at baseline. However, slight improvement in erectile functions with -blocker therapy was only seen in LUTS patients with ED.

Keywords: benign prostate hyperplasia, doxazosin|erectile dysfunction, lower urinary tract symptoms, treatment outcome

PDF | PDF | 中文摘要 |